Neomycin/Polymyxin B/Hydrocort
Brand names: Neomycin-Polymyxin-Hc, Neomycin-Polymyxin-Hydrocort
At a glance
- Medicare prescriptions, 2024
- 122,567
- Medicare drug cost
- $6.6M
- Average cost per prescription
- $53.89
- Clinicians who prescribed it
- 5,358
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
No FDA prescription label was found for this drug name.
Who prescribes it
- ENT (Otolaryngology) 21.8%
- Internal Medicine 16.7%
- Family Medicine 16.4%
- Nurse Practitioners 16.0%
- General Practice 9.7%
- Physician Assistants 6.5%
- Podiatrists 5.3%
- Facial Plastic Surgery 3.8%
- Emergency Medicine 1.0%
- Ophthalmology 0.6%
- Geriatric Medicine 0.4%
- Pulmonology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 12% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +0%
- New Jersey −1%
- South Carolina −2%
- Texas −2%
- New York −2%
- Kentucky (smallest change) −22%
- California (smallest change) −22%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.